Royalty Pharma (RPRX) Revenue (2019 - 2026)
Royalty Pharma (RPRX) revenue from Jun 30, 2019 to Mar 31, 2026. The TTM Royalty Pharma (RPRX) revenue is $2.44B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Royalty Pharma (RPRX) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +7.80% |
| 3 Years TTM | +1.14% |
| 5 Years TTM | +8.51% |
| All Time TTM | +9.14% |
Annual Revenue change of Royalty Pharma (RPRX)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $631M | -73.48% |
| 2025 | $2.38B | +5.06% |
| 2024 | $2.26B | -3.86% |
| 2023 | $2.35B | +5.24% |
| 2022 | $2.24B | -2.28% |
| 2021 | $2.29B | +7.87% |
| 2020 | $2.12B | +16.98% |
| 2019 | $1.81B | +1.08% |
| 2018 | $1.79B | N/A |
Comparison Royalty Pharma (RPRX) five years revenue CAGR with competitors
Royalty Pharma (RPRX) five years revenue CAGR is 2.82%.